NI-10 CLINICAL BENEFITS FROM ONE-SHOT BEVACIZUMAB BEFORE A RESECTION OF GLIOBLASTOMA

PURPOSE: We aimed to clarify of clinical impacts from preoperative administration of bevacizumab (BEV) in patients with newly diagnosed glioblastoma. METHODS: Subjects were 17 patients who met the entry criteria, and were administered with BEV (10 mg/kg) one time before surgery. Between phases before and after BEV administration, we compared KPS and volumes of hyperintense areas on FLAIR and enhanced areas on T1-weighted imaging with contrast media (Gd-T1WI). Tumor resection was carried out at least three weeks after BEV. Also between phases immediately before and after operation, volumes of hyperintense areas on FLAIR and enhanced areas on Gd-T1WI (= tumor removal rate) were compared. These were compared with those in the control group of patients who received tumor resection without BEV. RESULTS: One-shot BEV led to significant improvement of KPS and significant volume reductions of hyperintense areas on FLAIR (43.8±26.3%) and enhanced areas on Gd-T1WI (34.6±18.2%). No patients showed any adverse effects around surgery. On MRI after surgery, volume-reduction rates of hyperintense areas on FLAIR and enhanced areas on Gd-T1WI were 44.7±24.7% and 96.2±5.4%, respectively. Compared with control group, a significant difference was identified in the reduction rate of hyperintense areas, but not in that of enhanced areas. CONCLUSIONS: One-shot administration with BEV reduced both volumes of hyperintense areas on FLAIR and enhanced areas on Gd-T1WI, thereby improved KPS before surgery. Preoperative BEV was safe for tumor resections but did not affect to tumor removal rate. We speculated a significant volume reduction of hyperintense areas on FLAIR might have been led by continuous effect from BEV rather than an increase of resected volume.